Abstract

The impact of transfusing fresher vs older red blood cells (RBCs) on patient-important outcomes remains controversial. Two recently published large trials have provided new evidence. We summarized results of randomized trials evaluating the impact of the age of transfused RBCs. We searched MEDLINE, EMBASE, CINAHL, the Cochrane Database for Systematic Reviews, and Cochrane CENTRAL for randomized controlled trials enrolling patients who were transfused fresher vs older RBCs and reported outcomes of death, adverse events, and infection. Independently and in duplicate, reviewers determined eligibility, risk of bias, and abstracted data. We conducted random effects meta-analyses and rated certainty (quality or confidence) of evidence using the GRADE approach. Of 12 trials that enrolled 5229 participants, 6 compared fresher RBCs with older RBCs and 6 compared fresher RBCs with current standard practice. There was little or no impact of fresher vs older RBCs on mortality (relative risk [RR], 1.04; 95% confidence interval [CI], 0.94-1.14; P = .45; I2 = 0%, moderate certainty evidence) or on adverse events (RR, 1.02; 95% CI, 0.91-1.14; P = .74; I2 = 0%, low certainty evidence). Fresher RBCs appeared to increase the risk of nosocomial infection (RR, 1.09; 95% CI, 1.00-1.18; P = .04; I2 = 0%, risk difference 4.3%, low certainty evidence). Current evidence provides moderate certainty that use of fresher RBCs does not influence mortality, and low certainty that it does not influence adverse events but could possibly increase infection rates. The existing evidence provides no support for changing practices toward fresher RBC transfusion.

Background

Red blood cell (RBC) transfusion for surgical and critically ill patients remains a vital, and for some life-threatening situations, the only medical strategy for treating clinical symptoms related to bleeding and anemia. Nevertheless, recent randomized trials have suggested that restrictive transfusion thresholds (eg, transfusion at a hemoglobin concentration 7.0-9.0 g/dL [or 70-90 g/L] vs 10 g/dL) results in better outcomes than do higher thresholds.1-4  These counterintuitive results have fueled speculation regarding possible explanations. One explanation is the possible deleterious effects of transfusion of RBCs that have undergone relatively longer storage times.

Studies in controlled animal models have demonstrated that longer storage of RBCs leads to morphologic changes that could have a deleterious impact on microvascular perfusion and thus oxygen delivery. These changes include changes to the cell shape and membrane, an increase in adhesiveness, a decline in flexibility (rigidity that can hamper blood flow hemodynamics), and reductions in capillary flow.5-9  Further, older blood is associated with release of free iron that may predispose to vascular dysfunction, thrombosis, and nosocomial infections.5-9 

Finally, the storage medium could be deleterious by generating superoxides and inflammatory mediators that could result in oxidative damage.10-13  Observational studies,14-20  although potentially confounded,21,22  have suggested that these complicated mechanisms, often collectively referred to as “storage lesion,” may adversely affect patient-important outcomes including infection, organ failure, hospital stay, and death.14-20 

Prior evidence on the age of transfused RBCs has been dominated by uncontrolled observational studies that suggest better outcomes with fresher RBCs.23,24  However, a recently published 2015 Cochrane Systematic Review25  that focused exclusively on 16 randomized controlled trials was equivocal in their findings. This was a methodologically strong review, but because of lack of uniform definitions of “fresher” or “older” RBC storage and overlap in the distribution of the age of RBCs, the authors did not conduct any meta-analyses and noted that limitations in the evidence precluded definitive conclusions.

Subsequent to the Cochrane review,25  investigators have published 2 large trials26,27  that provided the impetus for our review. Here, we report on a systematic review and meta-analysis comparing the effects of fresher, newly stored RBCs vs older or standard-issue RBCs on mortality, adverse events, and infection.

Methods

Eligibility

We included randomized controlled trials enrolling patients of any age admitted to hospital and requiring a RBC transfusion comparing fresher vs older (or standard-issue) RBCs that reported mortality, adverse events, and/or post-transfusion infection. We did not exclude studies based on language or any other study characteristics.

Search

We accepted that the previously published Cochrane review25  had conducted a comprehensive search up to September 2014 and implemented their search strategy up to June 2015. Our electronic database search included MEDLINE, EMBASE, CINAHL (July 2014-June 2015), Cochrane Systematic Reviews (to June 2015), and the Cochrane Central Register of Controlled Trials (CENTRAL) (2014-2015) (see “Appendix” for details). We also searched PubMed for any very recent publications as of July 10 2015 and hand-searched reference lists of retrieved studies.

Study selection and data extraction

Two reviewers independently screened titles and abstracts in duplicate, obtained full texts of articles that either reviewer considered potentially eligible, and then determined eligibility from the full texts.

From the eligible studies, we abstracted data including single- or multicenter status, country, participant baseline characteristics, age of transfused RBCs, sample size, and outcome events. We also collected RBC characteristics—allogenic vs autologous, irradiated blood, whole blood, and leuko-reduced vs non–leuko-reduced RBCs—and the method of blood processing (eg, buffy coat, platelet-rich plasma).

Outcomes

We hypothesized that transfusion of fresher vs older RBCs would result in lower mortality, fewer adverse events, and a lower risk of infection. We used definitions from the primary studies for each outcome. Post-transfusion infections were defined broadly as any nosocomial infection requiring treatment after receiving the transfusion.

Risk of bias assessment

We addressed risk of bias using a modified Cochrane Risk of Bias Tool,28  which includes domains of random sequence generation, allocation concealment, blinding of participants and staff/lead researchers, blinding of outcome adjudicators, assessors, incomplete outcome data, selective outcome reporting, and early discontinuation. Response options were “yes,” “probably yes” (low risk of bias), “probably no,” and “no” (high risk of bias).29  We judged a study to be high risk of bias if the responses were “no” or “probably no” for the domains sequence generation, allocation concealment, blinding, or stopping early for benefit.

Reviewers independently made all eligibility, data abstraction, and risk of bias decisions and resolved disagreement through discussion and with third-party adjudication when necessary.

Rating quality of evidence

In accordance with the GRADE approach,30,31  our assessment of the certainty of the evidence included considerations of risk of bias, inconsistency, indirectness, imprecision, and publication bias, with overall ratings of evidence certainty as very low, low, moderate, or high.30,31 

Statistical analyses

We assessed agreement for eligibility and risk of bias using chance-corrected κ.32  All other statistical analyses were conducted utilizing the Review Manager33  (RevMan) version 5.3.2. We calculated the pooled risk ratios of dichotomous outcomes using Mantel-Haenszel random-effects models and report pooled estimates and the corresponding 95% confidence intervals (CIs). We evaluate heterogeneity statistics using the Cochrane Q χ2 test and I2.34 

Our primary analysis included only patients for whom outcome data were available (complete case) and counted patients in the groups to which they were randomized. For any clear differences in outcome between intervention and control groups, we planned to conduct sensitivity analyses using an approach in which we assumed worst plausible case results for patients in intervention groups with missing data.35  When outcomes were reported at different time points, we used data from the longest follow-up (eg, the trials for the mortality outcome).

Explanations of heterogeneity

To explain heterogeneity, we hypothesized that the following would be associated with a larger difference in favor of fresher RBCs: high- vs low-risk of bias; neonates/children vs adults; shorter storage of fresher RBCs (≤7 days vs 8-21 days for fresher RBCs) and longer storage of standard-issue RBCs (22-34 days vs 35-42 days); liberal vs restrictive transfusion strategy; and leukocyte-reduced RBCs vs non–leukocyte reduced RBCs. We conducted subgroup analysis only if I2 was > 0.

Results

Of the 352 citations identified in our updated search, 2 proved eligible (Figure 1).26,27  Of the 3 articles that underwent full text review, one36  did not report the patient-important outcomes we sought. Of the 16 trials included in the recent Cochrane review,25  we judged 6 to be ineligible36-41  because they did not report the outcomes examined in this review, leaving a total of 12 eligible studies.26,27,37,42-50 

Figure 1

Flow diagram of summary of evidence searching and final RCT selection.

Figure 1

Flow diagram of summary of evidence searching and final RCT selection.

Agreement (κ) for the title and abstract screening was 0.73, and for the completed full-text screening 0.71. Inter-rater agreement on individual domains of the risk of bias tool ranged from 0.51 to 0.69.

Table 1 presents trial characteristics. The trials included 5229 participants (1749  to 243027 ); 2451 patients were assigned to the fresher RBC arms and 2778 patients to the older RBC, or standard, arms. Six reports were feasibility trials intended to inform larger studies.37,42,44,45,47,49  Studies were conducted in Canada (3), USA (5), Brazil (1), Uganda (1), Australia (1), and European nations (with Canadian partnership) (1).

Table 1

Characteristics of included randomized clinical trials

Author surname; year published; country conducted Methods Eligibility criteria Interventions (fresh vs standard or older stored blood); reported definition; age of blood in treatment arms (fresher vs older or stored) 
Steiner; 2015; USA26  Multicenter, patients undergoing cardiac surgery, at 33 US hospitals. ≥12 y of age and eligible if weighed ≥40 kg and scheduled for complex cardiac surgery, those ≥18 y of age to have a score of 3 or higher on the TRUST scale (corresponds to a high likelihood of receiving RBC transfusions during surgery or within 96 h postoperatively). Randomized to units stored for ≤10 d or to units stored for ≥21 d for all transfusions from randomization through postoperative day 28, discharge or death (the first to occur), leukocyte reduced.
Definition: shorter- vs longer-term storage
Mean fresh: 7.8 ± 4.8 d SD
Mean older: 28.3 ± 6.7 d SD 
Hebert; 2005; Canada42  Multicenter, pilot study of patients admitted to ICU at 1 of 4 Canadian hospitals. Adults >16 y who required at least 1 unit of RBCs, accepted to participate in the study, and were either undergoing elective or urgent cardiac surgical procedures or admitted to an ICU. Randomized to either RBCs stored <8 d or standard issue RBCs based on standard blood bank procedure, leukocyte-reduced.
Definition: <8 d was deemed fresh blood and standard issue was considered older blood
Median fresh: 4 d
Median older: 19 d
Median difference: 15 d IQR 12-16 d 
Lacroix; 2015; Canada and Europe27  Multicenter, critically ill ICU patients in 64 hospitals. ≥18 y, and eligible if a first RBC transfusion was prescribed within 7 d after admission to the ICU and if they were expected to require invasive or noninvasive mechanical ventilation for at least 48 h. Randomized to RBC units stored for ≤8 d or to RBC units that were standard issue, units were leukocyte-reduced.
Definition: <8 d (fresh) vs usual transfusion practice (oldest available compatible blood)
Mean fresh: 6.1 ± 4.9 d SD
Mean older: 22.0 ± 8.4 d SD 
Aubron; 2012; Australia44  Multicenter, feasibility pilot, ICU admitted, critically ill patients. ≥18 y, and prescribed at least 1 unit of RBCs. Randomized to fresher blood (freshest available) vs older stored blood (oldest available), units were leukocyte-reduced.
Definition: fresh blood units found at the back of the transfusion service storage refrigerator and older/stored (nonexpired) units located at the front of the refrigerator (compatible, nonexpired [RBC] units with the longest storage duration at the time of transfusion request)
Mean fresh: 12.1 ± 3.8 d SD
Mean older: 23.0 ± 8.4 d SD 
Bennett-Guerrero; 2009; USA37  Single-center, reporting on the first phase of a 2-phase pilot, patients undergoing cardiac surgery. ≥18 y, a preoperative Parsonnet risk score >15 (indicative of greater morbidity and mortality risk), and scheduled for nonemergent coronary artery bypass graft and/or cardiac valve repair or replacement surgery using CPB. Randomized to no RBCs >21 days old vs standard of care for the phase 1 study, leukocyte-reduced.
Definition: blood age was defined as fresher or no RBCs >21 days old vs standard of care
Mean fresh: no RBCs > 21 d
Mean older: standard of care 
Dhabangi; 2013; Uganda45  Single-center pilot, open-label feasibility clinical trial, in children with severe malarial anemia. Aged six to 59 months enrolled if they had a positive blood smear for malaria, severe anemia (Hb ≤5 g/dL), lactic acidosis (blood lactate ≥5 mmol/L), and written informed consent from the parent or guardian. Randomized to RBCs that were of short storage age or long storage age.
Definition: short = 1-10 d vs long storage = 21-35 d
Mean fresh: 7.8 ± 1.8 d SD
Mean older: 27.2 ± 3.9 d SD 
Fergusson; 2012; Canada43  Multicenter, 6 Canadian tertiary NICUs/hospitals, in premature infants. Admitted to each of the participating neonatal ICUs with a birth weight of <1250 g and requiring one or more RBC transfusion for the treatment of anemia. Randomized to RBCs stored ≤7 d vs standard-issue/practice.
Definition: RBCs stored for ≤7 d (fresh blood) vs current standard-issue RBCs with storage time ranging from 2-42 d as per site
Mean fresh: 5.1 ± 2.0 d SD
Mean older: 14.6 ± 8.3 d SD 
Fernandes da Cunha; 2005; Brazil46  Single-center, university hospital setting, very-low-birth-weight children. Gestational age <37 wk, birth weight <1500 g, received at least one transfusion in hospital, and parents signed consent. Randomized to group 2 or fresh arm (up to 3 d age of blood) and to group 1 or older arm (blood stored for up to 28 d), leukocyte-reduced.
Definition: fresher blood was blood stored up to 3 d and older blood was stored up to 28 d
Mean fresh: 1.6 ± 0.6 d SD
Mean older: 9.0 ± 8.9 d SD 
Heddle; 2012; Canada47  Single-center pilot trial, consecutive patients admitted to an academic acute care hospital. Adult patients (≥17 y) hospitalized and requiring a blood transfusion. Randomized to either the freshest available or standard issue, leukocyte-reduced.
Definition: no clear numerical demarcation, freshest blood available vs standard issue blood
Mean fresh: 12 ± 6.8 d SD
Mean older: 26.6 ± 7.8 d SD 
Kor; 2012; USA48  Single-center, medical or surgical patients admitted to an ICU at Mayo clinic. Adults >18 y admitted for cardiac or neurologic surgery, endotracheally intubated and mechanically ventilated, and having arterial access in situ and Hb <9.5 g/dL. Randomized to either fresh arm (blood ≤5 d of storage) or standard issue, leukocytel-reduced.
Definition: Fresh arm is blood ≤5 d of storage and standard issue had a historic median storage duration of 21 d (range, 7-42)
Median fresh: 4 d, IQR 3-5 d
Median older: 26.5 d, IQR 21-36 d 
Schulman; 2002; USA49  Single-center, level I trauma hospital, published as a letter and not full manuscript, little details were provided. Patients admitted to trauma center and having blood type A, for support during acute illness/severe injuries. Randomized to young blood or old blood, leukocyte-reduced.
Definition: young blood was blood aged <11 d and old blood was blood aged >20 d
Not reported 
Strauss; 1996; USA50  Single-center study comparing the feasibility and safety of 2 techniques for providing small-volume RBC transfusions to very-low-birth-weight infants. Infants weighing 0.6-1.3 kg were potential trial subjects upon admission to the NICU, transfusion support during acute illness. Randomized to fresh blood or standard-practice storage, leukocyte-reduced.
Definition: fresh blood was ≤7 d and old blood was standard practice (<42 d)
Not reported 
Author surname; year published; country conducted Methods Eligibility criteria Interventions (fresh vs standard or older stored blood); reported definition; age of blood in treatment arms (fresher vs older or stored) 
Steiner; 2015; USA26  Multicenter, patients undergoing cardiac surgery, at 33 US hospitals. ≥12 y of age and eligible if weighed ≥40 kg and scheduled for complex cardiac surgery, those ≥18 y of age to have a score of 3 or higher on the TRUST scale (corresponds to a high likelihood of receiving RBC transfusions during surgery or within 96 h postoperatively). Randomized to units stored for ≤10 d or to units stored for ≥21 d for all transfusions from randomization through postoperative day 28, discharge or death (the first to occur), leukocyte reduced.
Definition: shorter- vs longer-term storage
Mean fresh: 7.8 ± 4.8 d SD
Mean older: 28.3 ± 6.7 d SD 
Hebert; 2005; Canada42  Multicenter, pilot study of patients admitted to ICU at 1 of 4 Canadian hospitals. Adults >16 y who required at least 1 unit of RBCs, accepted to participate in the study, and were either undergoing elective or urgent cardiac surgical procedures or admitted to an ICU. Randomized to either RBCs stored <8 d or standard issue RBCs based on standard blood bank procedure, leukocyte-reduced.
Definition: <8 d was deemed fresh blood and standard issue was considered older blood
Median fresh: 4 d
Median older: 19 d
Median difference: 15 d IQR 12-16 d 
Lacroix; 2015; Canada and Europe27  Multicenter, critically ill ICU patients in 64 hospitals. ≥18 y, and eligible if a first RBC transfusion was prescribed within 7 d after admission to the ICU and if they were expected to require invasive or noninvasive mechanical ventilation for at least 48 h. Randomized to RBC units stored for ≤8 d or to RBC units that were standard issue, units were leukocyte-reduced.
Definition: <8 d (fresh) vs usual transfusion practice (oldest available compatible blood)
Mean fresh: 6.1 ± 4.9 d SD
Mean older: 22.0 ± 8.4 d SD 
Aubron; 2012; Australia44  Multicenter, feasibility pilot, ICU admitted, critically ill patients. ≥18 y, and prescribed at least 1 unit of RBCs. Randomized to fresher blood (freshest available) vs older stored blood (oldest available), units were leukocyte-reduced.
Definition: fresh blood units found at the back of the transfusion service storage refrigerator and older/stored (nonexpired) units located at the front of the refrigerator (compatible, nonexpired [RBC] units with the longest storage duration at the time of transfusion request)
Mean fresh: 12.1 ± 3.8 d SD
Mean older: 23.0 ± 8.4 d SD 
Bennett-Guerrero; 2009; USA37  Single-center, reporting on the first phase of a 2-phase pilot, patients undergoing cardiac surgery. ≥18 y, a preoperative Parsonnet risk score >15 (indicative of greater morbidity and mortality risk), and scheduled for nonemergent coronary artery bypass graft and/or cardiac valve repair or replacement surgery using CPB. Randomized to no RBCs >21 days old vs standard of care for the phase 1 study, leukocyte-reduced.
Definition: blood age was defined as fresher or no RBCs >21 days old vs standard of care
Mean fresh: no RBCs > 21 d
Mean older: standard of care 
Dhabangi; 2013; Uganda45  Single-center pilot, open-label feasibility clinical trial, in children with severe malarial anemia. Aged six to 59 months enrolled if they had a positive blood smear for malaria, severe anemia (Hb ≤5 g/dL), lactic acidosis (blood lactate ≥5 mmol/L), and written informed consent from the parent or guardian. Randomized to RBCs that were of short storage age or long storage age.
Definition: short = 1-10 d vs long storage = 21-35 d
Mean fresh: 7.8 ± 1.8 d SD
Mean older: 27.2 ± 3.9 d SD 
Fergusson; 2012; Canada43  Multicenter, 6 Canadian tertiary NICUs/hospitals, in premature infants. Admitted to each of the participating neonatal ICUs with a birth weight of <1250 g and requiring one or more RBC transfusion for the treatment of anemia. Randomized to RBCs stored ≤7 d vs standard-issue/practice.
Definition: RBCs stored for ≤7 d (fresh blood) vs current standard-issue RBCs with storage time ranging from 2-42 d as per site
Mean fresh: 5.1 ± 2.0 d SD
Mean older: 14.6 ± 8.3 d SD 
Fernandes da Cunha; 2005; Brazil46  Single-center, university hospital setting, very-low-birth-weight children. Gestational age <37 wk, birth weight <1500 g, received at least one transfusion in hospital, and parents signed consent. Randomized to group 2 or fresh arm (up to 3 d age of blood) and to group 1 or older arm (blood stored for up to 28 d), leukocyte-reduced.
Definition: fresher blood was blood stored up to 3 d and older blood was stored up to 28 d
Mean fresh: 1.6 ± 0.6 d SD
Mean older: 9.0 ± 8.9 d SD 
Heddle; 2012; Canada47  Single-center pilot trial, consecutive patients admitted to an academic acute care hospital. Adult patients (≥17 y) hospitalized and requiring a blood transfusion. Randomized to either the freshest available or standard issue, leukocyte-reduced.
Definition: no clear numerical demarcation, freshest blood available vs standard issue blood
Mean fresh: 12 ± 6.8 d SD
Mean older: 26.6 ± 7.8 d SD 
Kor; 2012; USA48  Single-center, medical or surgical patients admitted to an ICU at Mayo clinic. Adults >18 y admitted for cardiac or neurologic surgery, endotracheally intubated and mechanically ventilated, and having arterial access in situ and Hb <9.5 g/dL. Randomized to either fresh arm (blood ≤5 d of storage) or standard issue, leukocytel-reduced.
Definition: Fresh arm is blood ≤5 d of storage and standard issue had a historic median storage duration of 21 d (range, 7-42)
Median fresh: 4 d, IQR 3-5 d
Median older: 26.5 d, IQR 21-36 d 
Schulman; 2002; USA49  Single-center, level I trauma hospital, published as a letter and not full manuscript, little details were provided. Patients admitted to trauma center and having blood type A, for support during acute illness/severe injuries. Randomized to young blood or old blood, leukocyte-reduced.
Definition: young blood was blood aged <11 d and old blood was blood aged >20 d
Not reported 
Strauss; 1996; USA50  Single-center study comparing the feasibility and safety of 2 techniques for providing small-volume RBC transfusions to very-low-birth-weight infants. Infants weighing 0.6-1.3 kg were potential trial subjects upon admission to the NICU, transfusion support during acute illness. Randomized to fresh blood or standard-practice storage, leukocyte-reduced.
Definition: fresh blood was ≤7 d and old blood was standard practice (<42 d)
Not reported 

CPB, cardiopulmonary bypass (machine); Hb, hemoglobin; ICU, intensive care unit; IQR, interquartile range; NICU, neonatal intensive care unit; RBC, red blood cell.

Transfused blood method of processing

No trial included information on whether buffy-coat or plasma-rich protein or other processing methods were used. Ten trials (83.0%) included information on leukoreduced status, 6 (50%) on irradiation status, and 6 (50%) on storage medium. Allogenic blood was used exclusively in 11 of 12 studies; one report49  did not specify.

Participant profile

Of the 12 eligible trials,26,27,37,42-50  3 enrolled neonates/infants with very low birth weight43,46,50  and 1 included patients 12 years and older26 ; the remainder enrolled adults. One trial was restricted to adults with malaria-associated anemia.45  Most trials enrolled patients experiencing acute critical illness and/or those with surgical hemorrhage.

Treatment and control arm interventions

Table 1 describes the interventions for included studies,26,27,37,42-50  and the definition of fresher RBCs vs older RBCs varies by study to the extent reported. Six trials compared fresher RBCs with older/longer storage RBCs,26,37,44-46,49  and 6 compared fresher RBCs with standard-issue or usual practice RBCs.27,42,43,47,48,50  For this report, however, older and standard-issue RBCs were considered the same because in both cases the oldest unit of RBCs in the inventory is issued for transfusion. Table 1 provides the mean (and standard deviation)/median (and interquartile range) ages (a reporting of age ranges) of transfused RBCs in both intervention arms.

Risk of bias

Studies were generally at low risk of bias (Figure 2).

Figure 2

Risk of bias assessment for included studies (domain risk percentages).

Figure 2

Risk of bias assessment for included studies (domain risk percentages).

Outcomes

Mortality.

The risk of death, presented in all 12 trials, was similar in the fresher and older RBC groups (RR, 1.04; 95% CI, 0.94-1.14; P = .45; heterogeneity P = .82; I2 0%, moderate certainty in evidence) (Figure 3 and Table 2). We report mortality at longest follow-up for all trials and as shown, results were similar irrespective of maximum length of follow-up (interaction P = .48; Figure 3).

Figure 3

Fresh vs older blood outcome mortality by specific duration of follow-up (based on the longest duration of follow-up per trial).

Figure 3

Fresh vs older blood outcome mortality by specific duration of follow-up (based on the longest duration of follow-up per trial).

Table 2

GRADE evidence profile

Question: Should fresh (new) blood vs older (stored/standard issue) blood be used for RBC transfusion? Patients: Patients of any age, attending hospitals/ICU/ED for RBC transfusion due to a medical emergency/surgery, etc.
Intervention: Fresh (new) blood
Comparator: Older (stored/standard issue) blood
Outcome(s): Mortality, adverse events, infections 
Quality assessment No. of patients Effects Quality 
No. of studies Design Risk of bias Inconsistency Indirectness Imprecision Publication bias Fresher (new) blood Older (stored/standard issue) blood Relative (95% CI) Estimation of absolute effects 
Mortality            
12 Randomized trials, sample n = 5221
events n = 1170 
No serious risk of bias* No serious inconsistency No serious indirectness Serious§ None detected 578/2451 (23.6%) 592/2778 (21.3%) RR 1.04 (0.94-1.14) 0.48% more (from 0.7% fewer to 1.7% more) Moderate 
Adverse events            
Randomized trials, sample n = 3585
events n = 583 
No serious risk of bias No serious inconsistency Serious indirectness Serious None detected 288/1781 (16.2%) 295/1804 (16.4%) RR 1.02 (0.91-1.14) 0.1% more (from 0.2% fewer to 0.4% more) Low 
Infections            
Randomized trials, sample n = 3940
events n = 1173 
No serious risk of bias No serious inconsistency No serious indirectness Serious None detected 605/1958 (30.9%) 568/1982 (28.7%) RR 1.09 (1.00-1.18) 4.3% more (from 0.1% to 8.6% more) Moderate 
Question: Should fresh (new) blood vs older (stored/standard issue) blood be used for RBC transfusion? Patients: Patients of any age, attending hospitals/ICU/ED for RBC transfusion due to a medical emergency/surgery, etc.
Intervention: Fresh (new) blood
Comparator: Older (stored/standard issue) blood
Outcome(s): Mortality, adverse events, infections 
Quality assessment No. of patients Effects Quality 
No. of studies Design Risk of bias Inconsistency Indirectness Imprecision Publication bias Fresher (new) blood Older (stored/standard issue) blood Relative (95% CI) Estimation of absolute effects 
Mortality            
12 Randomized trials, sample n = 5221
events n = 1170 
No serious risk of bias* No serious inconsistency No serious indirectness Serious§ None detected 578/2451 (23.6%) 592/2778 (21.3%) RR 1.04 (0.94-1.14) 0.48% more (from 0.7% fewer to 1.7% more) Moderate 
Adverse events            
Randomized trials, sample n = 3585
events n = 583 
No serious risk of bias No serious inconsistency Serious indirectness Serious None detected 288/1781 (16.2%) 295/1804 (16.4%) RR 1.02 (0.91-1.14) 0.1% more (from 0.2% fewer to 0.4% more) Low 
Infections            
Randomized trials, sample n = 3940
events n = 1173 
No serious risk of bias No serious inconsistency No serious indirectness Serious None detected 605/1958 (30.9%) 568/1982 (28.7%) RR 1.09 (1.00-1.18) 4.3% more (from 0.1% to 8.6% more) Moderate 

GRADE Working Group grades of evidence: High quality, further research is very unlikely to change our confidence in the estimate of effect; Moderate quality, further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate; Low quality, further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate; Very low quality, we are very uncertain about the estimate. The corresponding risk (and its 95% confidence interval) is based on the assumed risk (eg, the median/most representative control group risk across studies) in the comparison group and the relative effect of the intervention (and its 95% CI). For this, we used the median event rate in the control group when the number of studies was odd for an outcome and the average of the middle 2 studies when the number of studies was even.

*

Studies were at low risk of bias (Figure 2).

For all outcomes, visual inspection of the forest plot, the test for heterogeneity, and the I2 results of 0% all suggested consistent relative effects.

All studies enrolled relevant representative populations, but we rated down adverse events for indirectness because the studies used very different evaluations of adverse events. Adverse events were measured very differently across trials: old blood adverse events varied from 0.5% to 51%.

§

Confidence intervals are wide enough that they include for mortality and adverse events the possibility of important benefit and important harm and, for infections, no impact or important harm for younger blood.

We identified no reason to suspect publication bias.

Adverse events.

Three trials26,27,45  reported transfusion-related adverse events, which included acute transfusion reactions, seizures, acute cardiac events, hepatobiliary events, and renal and urinary events. Results indicated no difference in adverse events associated with age of RBCs (RR, 1.02; 95% CI, 0.91-1.14; P = .74; heterogeneity P = .80; I2 0%, low certainty in evidence) (Figure 4 and Table 2).

Figure 4

Fresh vs older blood outcome adverse events.

Figure 4

Fresh vs older blood outcome adverse events.

Infection.

Four trials reported nosocomial infections, two in neonates,43,46  one in cardiac surgery adult patients,26  and one in critically ill adults.27  One reported microbiologically confirmed infection,43  one clinical sepsis in neonates,46  and two reported clinically diagnosed infections.26,27  There was a 9% relative increase in the risk in patients who received fresher RBCs (RR, 1.09; 95% CI, 1.00-1.18; P = .04; heterogeneity P = .43; I2 0%, low certainty in evidence) (Figure 5 and Table 2).

Figure 5

Fresh vs older blood outcome nosocomial infection.

Figure 5

Fresh vs older blood outcome nosocomial infection.

Sensitivity analysis

Because very few patients were lost to follow-up (range, 1.0%-3.2%), worst plausible assumptions35  of patients lost to follow-up did not materially change the results for any outcome.

Subgroup analysis

We did not conduct subgroup analyses because the heterogeneity was easily explained by chance (I2 = 0% for all analyses).

GRADE evidence profile

The accumulated evidence provides moderate certainty evidence for death and low certainty for adverse events and infections (Table 2). Although the total number of trial participants and the number of deaths is large, the confidence interval around mortality and adverse events includes benefit that most would consider important, and an increase in infection that most would consider important. Thus, for each outcome, we rated down for imprecision.

Discussion

Main findings

Evidence from 12 randomized controlled trials26,27,37,42-50  that included patients with varying ages and experiencing a range of medical and surgical conditions found no benefit when fresher RBCs were transfused as opposed to older/standard-issue RBCs for either mortality (Figure 3 and Table 2) or adverse events (Figure 4 and Table 2). Results suggested that, if anything, fresher RBCs might lead to an increase rather than a decrease in nosocomial infections (Figure 5 and Table 2). Confidence intervals were sufficiently wide that for each outcome we rated down certainty of evidence for imprecision.

Strengths and concerns/limitations

Strengths of our study include explicit eligibility criteria, a comprehensive search built upon a prior review,25  and reproducible duplicate assessment of eligibility, and risk of bias. We rated the certainty (or confidence) of evidence using the GRADE approach,30,31  highlighting the moderate certainty evidence for the impact of fresher vs older RBC transfusion on mortality, and the low certainty for adverse events and infections.

There are several concerns/limitations. Concerns about variability include not only those of patient group but also blood processing methods and definitions of fresher and older blood. The primary limitation of our study is the variability across trials in a number of characteristics, and associated concerns about the appropriateness of a pooled estimate given this variability. One source of variability is the definition of fresher vs older RBCs. Researchers used various cut-points to define fresh vs older or stored blood and also used variable measures to report on blood age (eg, mean or median, etc).

A second source of variability is the method of blood processing, as well as the storage solutions, leukocyte reduction (though the majority were reported as leuko-depleted), and irradiation. Manipulations that increase RBC fragility, such as irradiation and washing, may exacerbate the risk of prolonged storage through the mechanism of increased hemolysis and free iron.51  Hemolysis and free iron have been associated with multiple complications of transfusions and diseases such as sickle cell anemia.52,53  Authors did not, however, report these aspects of blood processing consistently or completely enough to allow for further analyses.

A third source of variability is the different populations, which included neonates and the pediatric and adult populations. Thus, one might raise concerns about combining results across studies given the variability in the age of fresher and older blood and differences in age between fresher and older blood, the variability in blood processing procedures, and the variability in patient characteristics and study methods. It is possible that the impact of fresher or older blood on mortality and other outcomes might differ across these factors. Conversely, it is possible that across these variations, the impact of fresher vs older blood is similar. The consistency of results across studies suggests that, in this instance, this is likely to be the case.

Another limitation is the sample size: although the total sample size and number of events are large, depending on one’s perspective, the data remain consistent with small but possibly important benefits of fresher RBCs on death rates. Using the median death rate of 12% in the old blood arms of the eligible trials, and the boundary of the confidence interval most favoring fresh blood, the largest benefit of fresh blood consistent with the results would be a reduction in mortality of 7 per 1000. Some might consider such a small mortality benefit not worth the economic and logistic burden of using exclusively fresh blood; others might disagree. Similarly, for infections, although an 8.6% absolute increase in infections with fresh blood (the upper boundary of the confidence interval) would be of great concern, an increase in infections of 1 per 1000 (the lower boundary of the confidence) would probably not. The backdrop is that RBC transfusion is one of the most common medical treatments, with approximately 85 million RBC units transfused annually worldwide54 ; hence, the impact of even a small risk could have significant patient impact globally.

Some suggest that there is increased chance of receiving older RBCs the more units of RBCs transfused.55,56  There may be a dose-response association operating in that in line with the storage lesion,14-20  and that although one unit of older RBCs would not be sufficient to cause adverse outcomes, transfusion of a number of units might.55,56  This is particularly relevant in regard to the safety of massive transfusions of older RBCs to infants and small children. These individuals might receive very large doses of older RBCs from a single unit of blood, and that unit may be particularly old (35-42 days). For example, observational data have suggested that infection rates are strikingly higher in infants and children undergoing cardiac surgery who receive washed transfusions of older RBCs (25-38 days).57  Researchers found that washing the RBCs that were oldest (eg, >29 days) was related to an increase in morbidity when compared with unwashed RBCs.57  An individual patient meta-analysis from studies that enrolled infants and small children who received very large volumes of washed RBCs may be a feasible approach to explore these issues.

Relation to prior work

Prior observational cohort studies, reviews, and meta-analyses based on cohort studies suggested that fresher vs older transfused RBCs reduced the risk of death and post-transfusion complications.19,23,58-61  Observational studies are, however, susceptible to prognostic differences between groups that could explain the apparent effect of RBC age. Thus, we relied exclusively on randomized trials to address the study question.

Our review results are largely consistent with those of a recent Cochrane review25  of randomized trials of the use of fresher vs older or stored RBCs for transfusion. Researchers reported no clear difference in mortality between fresher RBCs when compared with older RBCs.25  The prior Cochrane review being methodologically strong, did not, however, include the recently published large clinical trials,26,27  conduct meta-analysis, or use the GRADE approach; and the more recent trials26,27  substantially increased certainty in estimates of effect.

Ongoing trials

Several larger sample-sized international trials are ongoing that could address the limitations we have raised in our review. The methodologic quality of recently published trials26,27  and upcoming ones are needed to address the question of blood age on clinically significant outcomes. An ongoing Canadian multicenter trial (INFORM) of note in persons requiring a RBC transfusion seeks to determine the effect on in-hospital death rates of transfusing the freshest available RBCs compared with standard-issue RBCs.62  In addition, several trials (recruiting and not yet recruiting) are registered in the ClinicalTrials.gov regulatory database63  and worth flagging (eg, NCT01638416/examining whether patients who receive fresher RBCs do better than patients who receive standard issue RBCs; NCT01976234/examining transfusion of RBCs and the association with postoperative infections; NCT02393508/examining the impact of RBC age in patients receiving chronic blood transfusions in the outpatient setting) that, on completion, would help clarify our findings.

Conclusions

Our systematic review and meta-analysis provided no support for blood transfusion services implementing limits, or instituting preferential utilization, of RBC units that are fresh or stored for shorter periods. The consistent results across studies suggest that the impact of blood age does not differ across patient groups, nor that very fresh vs fresh RBCs, or old vs very old red RBCs, differ in their effects. Large ongoing studies may, however, challenge these results. It is more likely that they will show consistent results that further narrow the confidence intervals around key outcomes—and particularly mortality—and establish definitively that there is no need to change blood transfusion practices to ensure the use of younger or the freshest RBCs.

Acknowledgments

Ms Supriya Rave of Canada assisted in the title and abstract as well as full-text screening phases. Interpretations and conclusions drawn are not to be ascribed to her in any manner.

Authorship

Contribution: P.E.A. is the lead researcher on this research project and all coauthors have contributed in various means to the design, conduct and analysis, and writing/editing of the manuscript. Their contribution in terms of extent is indicated by the position in authorship. G.H.G. is the lead scientist with strong content guidance emerging from N.B. and N.M.H.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Paul Elias Alexander, Health Research Methods, Health Sciences Building, Department of Clinical Epidemiology and Biostatistics, McMaster University, 1280 Main St, West Hamilton, ON, L8N 3Z5, Canada; e-mail: elias98_99@yahoo.com.

Appendix: examples of the MEDLINE and EMBASE search built on the Cochrane25  search strategy, then limited to randomized controlled evidence

MEDLINE (Ovid SP)

  1. ERYTHROCYTE TRANSFUSION/

  2. ((blood or erythrocyte* or red cell* or red blood cell* or RBC*) adj1 (transfus* or infus* or retransfus*)).ti,ab.

  3. BLOOD TRANSFUSION/ or BLOOD COMPONENT TRANSFUSION/

  4. ERYTHROCYTES/

  5. (red cell* or red blood cell* or erythrocyte* or RBC* or whole blood).tw.

  6. 4 or 5

  7. 3 and 6

  8. (RBC* or red cell* or red blood cell* or erythrocyte* or whole blood).ti.

  9. 1 or 2 or 7 or 8

  10. exp Blood Preservation/

  11. *Time Factors/

  12. (age or aged or aging or fresh* or old or older or oldest or new or newer or newest or young or younger or youngest or store* or storage or storing or preserv*).ti.

  13. 10 or 11 or 12

  14. 9 and 13

  15. ((red cell* or red blood cell* or erythrocyte* or RBC* or blood or transfus*) adj5 (age or aged or aging or fresh* or old or older or oldest or new or newer or newest or young or younger or youngest or store* or storage or storing or preserv*)).ti.

  16. ((red cell* or red blood cell* or erythrocyte* or RBC* or whole blood) adj3 (store* or storage or storing or preserv* or fresh* or old or older or oldest or new or newer or newest or young or younger or youngest)).ab.

  17. 14 or 15 or 16

EMBASE (Ovid SP)

  1. ERYTHROCYTE TRANSFUSION/

  2. ((blood or erythrocyte* or red cell* or red blood cell* or RBC*) adj1 (transfus* or infus* or retransfus*)).ti,ab.

  3. BLOOD TRANSFUSION/ or BLOOD COMPONENT THERAPY/

  4. ERYTHROCYTE/ or ERYTHROCYTE CONCENTRATE/

  5. (red cell* or red blood cell* or erythrocyte* or RBC* or whole blood).tw.

  6. 4 or 5

  7. 3 and 6

  8. (RBC* or red cell* or red blood cell* or erythrocyte* or whole blood).ti.

  9. 1 or 2 or 7 or 8

  10. BLOOD STORAGE/

  11. ERYTHROCYTE PRESERVATION/

  12. STORAGE TIME/

  13. *TIME/

  14. (age or aged or aging or fresh* or old or older or oldest or new or newer or newest or young or younger or youngest or store* or storage or storing or preserv*).ti.

  15. 10 or 11 or 12 or 13 or 14

  16. 9 and 15

  17. ((red cell* or red blood cell* or erythrocyte* or RBC* or blood or transfus*) adj5 (age or aged or aging or fresh* or old or older or oldest or new or newer or newest or young or younger or youngest or store* or storage or storing or preserv*)).ti.

  18. ((red cell* or red blood cell* or erythrocyte* or RBC* or whole blood) adj3 (store* or storage or storing or preserv* or fresh* or old or older or oldest or new or newer or newest or young or younger or youngest)).ab.

  19. 16 or 17 or 18

References

References
1
Holst
 
LB
Haase
 
N
Wetterslev
 
J
, et al. 
TRISS Trial Group; Scandinavian Critical Care Trials Group
Lower versus higher hemoglobin threshold for transfusion in septic shock.
N Engl J Med
2014
, vol. 
371
 
15
(pg. 
1381
-
1391
)
2
Lacroix
 
J
Hébert
 
PC
Hutchison
 
JS
, et al. 
TRIPICU Investigators; Canadian Critical Care Trials Group; Pediatric Acute Lung Injury and Sepsis Investigators Network
Transfusion strategies for patients in pediatric intensive care units.
N Engl J Med
2007
, vol. 
356
 
16
(pg. 
1609
-
1619
)
3
Holst
 
LB
Petersen
 
MW
Haase
 
N
Perner
 
A
Wetterslev
 
J
Restrictive versus liberal transfusion strategy for red blood cell transfusion: systematic review of randomised trials with meta-analysis and trial sequential analysis.
BMJ
2015
, vol. 
350
 pg. 
h1354
 
4
Brunskill
 
SJ
Millette
 
SL
Shokoohi
 
A
, et al. 
Red blood cell transfusion for people undergoing hip fracture surgery.
Cochrane Database Syst Rev
2015
, vol. 
4
 pg. 
CD009699
 
5
Qu
 
L
Triulzi
 
DJ
Clinical effects of red blood cell storage.
Cancer Control
2015
, vol. 
22
 
1
(pg. 
26
-
37
)
6
Sparrow
 
RL
Red blood cell storage duration and trauma.
Transfus Med Rev
2015
, vol. 
29
 
2
(pg. 
120
-
126
)
7
Hod
 
EA
Spitalnik
 
SL
Harmful effects of transfusion of older stored red blood cells: iron and inflammation.
Transfusion
2011
, vol. 
51
 
4
(pg. 
881
-
885
)
8
Wang
 
D
Cortés-Puch
 
I
Sun
 
J
, et al. 
Transfusion of older stored blood worsens outcomes in canines depending on the presence and severity of pneumonia.
Transfusion
2014
, vol. 
54
 
7
(pg. 
1712
-
1724
)
9
Grimshaw
 
K
Sahler
 
J
Spinelli
 
SL
Phipps
 
RP
Blumberg
 
N
New frontiers in transfusion biology: identification and significance of mediators of morbidity and mortality in stored red blood cells.
Transfusion
2011
, vol. 
51
 
4
(pg. 
874
-
880
)
10
Khan
 
SY
Kelher
 
MR
Heal
 
JM
, et al. 
Soluble CD40 ligand accumulates in stored blood components, primes neutrophils through CD40, and is a potential cofactor in the development of transfusion-related acute lung injury.
Blood
2006
, vol. 
108
 
7
(pg. 
2455
-
2462
)
11
Bercovitz
 
RS
Kelher
 
MR
Khan
 
SY
Land
 
KJ
Berry
 
TH
Silliman
 
CC
The pro-inflammatory effects of platelet contamination in plasma and mitigation strategies for avoidance.
Vox Sang
2012
, vol. 
102
 
4
(pg. 
345
-
353
)
12
Kücükakin
 
B
Kocak
 
V
Lykkesfeldt
 
J
, et al. 
Storage-induced increase in biomarkers of oxidative stress and inflammation in red blood cell components.
Scand J Clin Lab Invest
2011
, vol. 
71
 
4
(pg. 
299
-
303
)
13
Ogunro
 
PS
Ogungbamigbe
 
TO
Muhibi
 
MA
The influence of storage period on the antioxidants level of red blood cells and the plasma before transfusion.
Afr J Med Med Sci
2010
, vol. 
39
 
2
(pg. 
99
-
104
)
14
Vamvakas
 
EC
Carven
 
JH
Transfusion and postoperative pneumonia in coronary artery bypass graft surgery: effect of the length of storage of transfused red cells.
Transfusion
1999
, vol. 
39
 
7
(pg. 
701
-
710
)
15
Mynster
 
T
Nielsen
 
HJ
Danish RANX05 Colorectal Cancer Study Group
Storage time of transfused blood and disease recurrence after colorectal cancer surgery.
Dis Colon Rectum
2001
, vol. 
44
 
7
(pg. 
955
-
964
)
16
Leal-Noval
 
SR
Jara-López
 
I
García-Garmendia
 
JL
, et al. 
Influence of erythrocyte concentrate storage time on postsurgical morbidity in cardiac surgery patients.
Anesthesiology
2003
, vol. 
98
 
4
(pg. 
815
-
822
)
17
Mynster
 
T
Nielsen
 
HJ
The impact of storage time of transfused blood on postoperative infectious complications in rectal cancer surgery. Danish RANX05 Colorectal Cancer Study Group.
Scand J Gastroenterol
2000
, vol. 
35
 
2
(pg. 
212
-
217
)
18
Lee
 
SJ
Seo
 
H
Kim
 
HC
, et al. 
Effect of intraoperative red blood cell transfusion on postoperative complications after open radical cystectomy: old versus fresh stored blood.
Clin Genitourin Cancer
2015
, vol. 
13
 
6
(pg. 
581
-
587
)
19
Koch
 
CG
Li
 
L
Sessler
 
DI
, et al. 
Duration of red-cell storage and complications after cardiac surgery.
N Engl J Med
2008
, vol. 
358
 
12
(pg. 
1229
-
1239
)
20
Manlhiot
 
C
McCrindle
 
BW
Menjak
 
IB
, et al. 
Longer blood storage is associated with suboptimal outcomes in high-risk pediatric cardiac surgery.
Ann Thorac Surg
2012
, vol. 
93
 
5
(pg. 
1563
-
1569
)
21
Steiner
 
ME
Stowell
 
C
Does red blood cell storage affect clinical outcome? When in doubt, do the experiment.
Transfusion
2009
, vol. 
49
 
7
(pg. 
1286
-
1290
)
22
Vamvakas
 
EC
Meta-analysis of clinical studies of the purported deleterious effects of “old” (versus “fresh”) red blood cells: are we at equipoise?
Transfusion
2010
, vol. 
50
 
3
(pg. 
600
-
610
)
23
Wang
 
D
Sun
 
J
Solomon
 
SB
Klein
 
HG
Natanson
 
C
Transfusion of older stored blood and risk of death: a meta-analysis.
Transfusion
2012
, vol. 
52
 
6
(pg. 
1184
-
1195
)
24
Middelburg
 
RA
van de Watering
 
LM
Briët
 
E
van der Bom
 
JG
Storage time of red blood cells and mortality of transfusion recipients.
Transfus Med Rev
2013
, vol. 
27
 
1
(pg. 
36
-
43
)
25
Brunskill
 
SJ
Wilkinson
 
KL
Doree
 
C
Trivella
 
M
Stanworth
 
S
Transfusion of fresher versus older red blood cells for all conditions.
Cochrane Database Syst Rev
2015
, vol. 
5
 pg. 
CD010801
 
26
Steiner
 
ME
Ness
 
PM
Assmann
 
SF
, et al. 
Effects of red-cell storage duration on patients undergoing cardiac surgery.
N Engl J Med
2015
, vol. 
372
 
15
(pg. 
1419
-
1429
)
27
Lacroix
 
J
Hébert
 
PC
Fergusson
 
DA
, et al. 
ABLE Investigators; Canadian Critical Care Trials Group
Age of transfused blood in critically ill adults.
N Engl J Med
2015
, vol. 
372
 
15
(pg. 
1410
-
1418
)
28
Cochrane Bias Methods Group
 
Assessing Risk of Bias in Included Studies. Available at: http://bmg.cochrane.org/assessing-risk-bias-included-studies. Accessed on July 15, 2015
29
Guyatt
 
G
Busse
 
J
 
Methods Commentary: Risk of Bias in Randomized Trials 1.Available at: http://distillercer.com/resources/methodological-resources/risk-of-bias-commentary/. Accessed on January 31, 2015
30
Guyatt
 
G
Oxman
 
AD
Akl
 
EA
, et al. 
GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables.
J Clin Epidemiol
2011
, vol. 
64
 
4
(pg. 
383
-
394
)
31
Andrews
 
JC
Schünemann
 
HJ
Oxman
 
AD
, et al. 
GRADE guidelines 15: going from evidence to recommendation-determinants of a recommendation's directionand strength.
J Clin Epidemiol
2013
, vol. 
66
 
7
(pg. 
726
-
735
)
32
Landis
 
JR
Koch
 
GG
The measurement of observer agreement for categorical data.
Biometrics
1977
, vol. 
33
 
1
(pg. 
159
-
174
)
33
RevMan 5. url: http://tech.cochrane.org/revman/download. Accessed on June 2, 2015
34
Langan
 
D
Higgins
 
JP
Simmonds
 
M
An empirical comparison of heterogeneity variance estimators in 12 894 meta-analyses.
Res Synth Methods
2015
, vol. 
6
 
2
(pg. 
195
-
205
)
35
Akl
 
EA
Briel
 
M
You
 
JJ
, et al. 
Potential impact on estimated treatment effects of information lost to follow-up in randomised controlled trials (LOST-IT): systematic review.
BMJ
2012
, vol. 
344
 pg. 
e2809
 
36
Neuman
 
R
Hayek
 
S
Rahman
 
A
, et al. 
Effects of storage-aged red blood cell transfusions on endothelial function in hospitalized patients.
Transfusion
2015
, vol. 
55
 
4
(pg. 
782
-
790
)
37
Bennett-Guerrero
 
E
Stafford-Smith
 
M
Waweru
 
PM
, et al. 
A prospective, double-blind, randomized clinical feasibility trial of controlling the storage age of red blood cells for transfusion in cardiac surgical patients.
Transfusion
2009
, vol. 
49
 
7
(pg. 
1375
-
1383
)
38
Liu
 
EA
Mannino
 
FL
Lane
 
TA
Prospective, randomized trial of the safety and efficacy of a limited donor exposure transfusion program for premature neonates.
J Pediatr
1994
, vol. 
125
 
1
(pg. 
92
-
96
)
39
Strauss
 
RG
Burmeister
 
LF
Johnson
 
K
Cress
 
G
Cordle
 
D
Feasibility and safety of AS-3 red blood cells for neonatal transfusions.
J Pediatr
2000
, vol. 
136
 
2
(pg. 
215
-
219
)
40
Walsh
 
TS
McArdle
 
F
McLellan
 
SA
, et al. 
Does the storage time of transfused red blood cells influence regional or global indexes of tissue oxygenation in anemic critically ill patients?
Crit Care Med
2004
, vol. 
32
 
2
(pg. 
364
-
371
)
41
Yürük
 
K
Milstein
 
DM
Bezemer
 
R
Bartels
 
SA
Biemond
 
BJ
Ince
 
C
Transfusion of banked red blood cells and the effects on hemorrheology and microvascular hemodynamics in anemic hematology outpatients.
Transfusion
2013
, vol. 
53
 
6
(pg. 
1346
-
1352
)
42
Hébert
 
PC
Chin-Yee
 
I
Fergusson
 
D
, et al. 
A pilot trial evaluating the clinical effects of prolonged storage of red cells.
Anesth Analg
2005
, vol. 
100
 
5
(pg. 
1433
-
1438
)
43
Fergusson
 
DA
Hébert
 
P
Hogan
 
DL
, et al. 
Effect of fresh red blood cell transfusions on clinical outcomes in premature, very low-birth-weight infants: the ARIPI randomized trial.
JAMA
2012
, vol. 
308
 
14
(pg. 
1443
-
1451
)
44
Aubron
 
C
Syres
 
G
Nichol
 
A
, et al. 
A pilot feasibility trial of allocation of freshest available red blood cells versus standard care in critically ill patients.
Transfusion
2012
, vol. 
52
 
6
(pg. 
1196
-
1202
)
45
Dhabangi
 
A
Mworozi
 
E
Lubega
 
IR
Cserti-Gazdewich
 
CM
Maganda
 
A
Dzik
 
WH
The effect of blood storage age on treatment of lactic acidosis by transfusion in children with severe malarial anaemia: a pilot, randomized, controlled trial.
Malar J
2013
, vol. 
12
 pg. 
55
 
46
Fernandes da Cunha
 
DH
Nunes Dos Santos
 
AM
Kopelman
 
BI
, et al. 
Transfusions of CPDA-1 red blood cells stored for up to 28 days decrease donor exposures in very low-birth-weight premature infants.
Transfus Med
2005
, vol. 
15
 
6
(pg. 
467
-
473
)
47
Heddle
 
NM
Cook
 
RJ
Arnold
 
DM
, et al. 
The effect of blood storage duration on in-hospital mortality: a randomized controlled pilot feasibility trial.
Transfusion
2012
, vol. 
52
 
6
(pg. 
1203
-
1212
)
48
Kor
 
DJ
Kashyap
 
R
Weiskopf
 
RB
, et al. 
Fresh red blood cell transfusion and short-term pulmonary, immunologic, and coagulation status: a randomized clinical trial.
Am J Respir Crit Care Med
2012
, vol. 
185
 
8
(pg. 
842
-
850
)
49
Schulman
 
CI
Nathe
 
K
Brown
 
M
Cohn
 
SM
Impact of age of transfused blood in the trauma patient.
J Trauma
2002
, vol. 
52
 
6
(pg. 
1224
-
1225
)
50
Strauss
 
RG
Burmeister
 
LF
Johnson
 
K
, et al. 
AS-1 red cells for neonatal transfusions: a randomized trial assessing donor exposure and safety.
Transfusion
1996
, vol. 
36
 
10
(pg. 
873
-
878
)
51
Harm
 
SK
Raval
 
JS
Cramer
 
J
Waters
 
JH
Yazer
 
MH
Haemolysis and sublethal injury of RBCs after routine blood bank manipulations.
Transfus Med
2012
, vol. 
22
 
3
(pg. 
181
-
185
)
52
Rother
 
RP
Bell
 
L
Hillmen
 
P
Gladwin
 
MT
The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease.
JAMA
2005
, vol. 
293
 
13
(pg. 
1653
-
1662
)
53
Prestia
 
K
Bandyopadhyay
 
S
Slate
 
A
, et al. 
Transfusion of stored blood impairs host defenses against Gram-negative pathogens in mice.
Transfusion
2014
, vol. 
54
 
11
(pg. 
2842
-
2851
)
54
Carson
 
JL
Grossman
 
BJ
Kleinman
 
S
, et al. 
Clinical Transfusion Medicine Committee of the AABB
Red blood cell transfusion: a clinical practice guideline from the AABB*.
Ann Intern Med
2012
, vol. 
157
 
1
(pg. 
49
-
58
)
55
Vamvakas
 
EC
Purported deleterious effects of “old” versus “fresh” red blood cells: an updated meta-analysis.
Transfusion
2011
, vol. 
51
 
5
(pg. 
1122
-
1123
)
56
Patterson
 
JA
Irving
 
DO
Isbister
 
JP
, et al. 
Age of blood and adverse outcomes in a maternity population.
Transfusion
2015
, vol. 
55
 
11
(pg. 
2730
-
2737
)
57
Cholette
 
JM
Pietropaoli
 
AP
Henrichs
 
KF
, et al. 
Longer RBC storage duration is associated with increased postoperative infections in pediatric cardiac surgery.
Pediatr Crit Care Med
2015
, vol. 
16
 
3
(pg. 
227
-
235
)
58
Brown
 
CH
Grega
 
M
Selnes
 
OA
, et al. 
Length of red cell unit storage and risk for delirium after cardiac surgery.
Anesth Analg
2014
, vol. 
119
 
2
(pg. 
242
-
250
)
59
van de Watering
 
LM
Age of blood: does older blood yield poorer outcomes?
Curr Opin Hematol
2013
, vol. 
20
 
6
(pg. 
526
-
532
)
60
Damiani
 
E
Adrario
 
E
Luchetti
 
MM
, et al. 
Plasma free hemoglobin and microcirculatory response to fresh or old blood transfusions in sepsis.
PLoS One
2015
, vol. 
10
 
5
 
e0122655
61
Lelubre
 
C
Vincent
 
JL
Relationship between red cell storage duration and outcomes in adults receiving red cell transfusions: a systematic review.
Crit Care
2013
, vol. 
17
 
2
pg. 
R66
 
62
INFORM
 
BioMed Central. ISRCTN Registry. Available at: http://www.controlled-trials.com/ISRCTN08118744. Accessed on August 22, 2015
63
ClinicalTrials.gov
 
Available at: https://clinicaltrials.gov/. Accessed on August 22, 2015